FIELD: medicine, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to cardiosurgery and can be used in operations on heart. Invention proposes a cardioplegic solution for intraoperation protection of myocardium containing the following components, ml: 5% KCl solution, 11-14; 5% NaHCO3 solution, 4-6; 25% MgSO4 solution, 1-2; 15% mannitol solution, 12-15; 40% glucose solution, 0.5-2; 10% calcium gluconate solution, 1-2, and 0.9% NaCl solution up to 100 ml Prepared solution is mixed with autoblood in the ratio 1:4. The claimed invention allows decreasing dose of inotropic support in post-operation period and to reduce possibility of negative results after operation on heart.
EFFECT: valuable medicinal properties of solution.
1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF MYOCARDIUM PROTECTION DURING OPERATIONS ON HEART | 2004 |
|
RU2335290C2 |
METHOD FOR CARDIOPLEGIC ARREST (VERSIONS) | 2015 |
|
RU2571058C1 |
METHOD FOR COMBINED MYOCARDIAL PROTECTION AND A DEVICE FOR PERFORMING BLOOD COLD CARDIOPLEGIA IN HEART OPERATIONS IN NEWBORNS AND INFANTS | 2019 |
|
RU2706017C1 |
METHOD OF CARDIOPLEGIC ANTEGRADE MYOCARDIAL PROTECTION | 2022 |
|
RU2803867C1 |
CRYSTALLOID CARDIOPLEGIC SOLUTION | 2009 |
|
RU2423135C2 |
METHOD OF CARRYING OUT CARDIOPLEGIA | 2009 |
|
RU2434589C2 |
CARDIOPLEGIC SOLUTION (VERSIONS) | 2014 |
|
RU2574957C1 |
CRYSTALLOID CARDIOPLEGIC SOLUTIONS, CONTAINING DODECAPEPTIDES (VERSIONS) | 2013 |
|
RU2549470C1 |
METHOD FOR PREVENTING REPERFUSION MYOCARDIAL DAMAGE IN CONGENITAL HEART DISEASE SURGERY | 2019 |
|
RU2718308C1 |
CARDIOPLEGIA AGENT (VERSIONS) | 2014 |
|
RU2568911C1 |
Authors
Dates
2008-03-27—Published
2004-10-25—Filed